- Conditions
- Head And Neck Cancer
- Interventions
- Erlotinib, RAD001
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 50
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
- Interventions
- Everolimus, Ranibizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Sacramento, California • Denver, Colorado + 1 more
- Conditions
- Sarcoma
- Interventions
- RAD001
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Aging
- Interventions
- Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet, Everolimus 0.5 MG Oral Tablet, Everolimus 1 MG Oral Tablet, Everolimus 2 MG Oral Tablet
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer
- Interventions
- Capecitabine, Exemestane, Everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Diego, California • Fort Myers, Florida + 15 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- Everolimus, Exemestane, Metformin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Belzutifan, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more
- Conditions
- Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
- Interventions
- Everolimus
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Oakland, California • San Diego, California + 14 more
- Conditions
- Advanced Neuroendocrine Tumors of Pancreatic Origin
- Interventions
- Everolimus, Everolimus Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Anaheim, California • Los Angeles, California + 20 more
- Conditions
- Tuberous Sclerosis Complex-associated Refractory Seizures
- Interventions
- RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Breast Cancer
- Interventions
- Everolimus, Placebo, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 719 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 21 more
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- RAD001, Imatinib 600mg/day (Glevec is the brand name for imatinib), Imatinib 800mg/day (Glevec is the brand name for imatinib)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Breast Cancer, Ovarian Cancer
- Interventions
- niraparib, everolimus
- Drug
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Non Clear Cell Renal Cell Carcinoma (nccRCC)
- Interventions
- lenvatinib, everolimus
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more
- Conditions
- Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms
- Interventions
- Everolimus 10 mg, Octreotide Depot
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Breast Cancer
- Interventions
- everolimus, abraxane
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey
- Conditions
- Breast Cancer
- Interventions
- ribociclib (LEE011), Exemestane, Everolimus (RAD001)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 8
- States / cities
- Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more
- Conditions
- Advanced Gastric Cancer
- Interventions
- Everolimus, Everolimus placebo, Best Supportive Care (BSC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Fayetteville, Arkansas • Redlands, California • Detroit, Michigan + 5 more
- Conditions
- Living-Donor Kidney Transplant, Kidney Transplant Recipients
- Interventions
- lulizumab pegol, antithymocyte globulin (rabbit), methylprednisolone, tocilizumab, Prednisone, everolimus, belatacept, mycophenolate mofetil, mycophenolic acid
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 4 more
- Conditions
- Advanced Breast Cancer
- Interventions
- Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Thyroid Cancer
- Interventions
- RAD001
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Endometrial Cancer
- Interventions
- Metformin, Letrozole, Everolimus
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 6
- States / cities
- Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- Combination therapy
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico